66 related articles for article (PubMed ID: 25450283)
21. Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray.
Gao Y; Liao Y; Shen JK; Feng Y; Choy E; Cote G; Harmon D; Mankin HJ; Hornicek FJ; Duan Z
J Orthop Res; 2016 Sep; 34(9):1606-12. PubMed ID: 26790551
[TBL] [Abstract][Full Text] [Related]
22. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
[TBL] [Abstract][Full Text] [Related]
23. Trps1 is associated with the multidrug resistance of osteosarcoma by regulating MDR1 gene expression.
Jia M; Hu J; Li W; Su P; Zhang H; Zhang X; Zhou G
FEBS Lett; 2014 Mar; 588(5):801-10. PubMed ID: 24491996
[TBL] [Abstract][Full Text] [Related]
24. Expression of MSH2 and MSH6 on a tissue microarray in patients with osteosarcoma.
Jentzsch T; Robl B; Husmann M; Bode-Lesniewska B; Fuchs B
Anticancer Res; 2014 Dec; 34(12):6961-72. PubMed ID: 25503122
[TBL] [Abstract][Full Text] [Related]
25. The anti-inflammatory effects of inhaled corticosteroids versus anti-leukotrienes on the lymphocyte P-glycoprotein (PGP) expression in asthmatic children.
Kopriva F; Dzubak P; Potesil J; Hajduch M
J Asthma; 2009 May; 46(4):366-70. PubMed ID: 19484671
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy.
Bacci G; Longhi A; Fagioli F; Briccoli A; Versari M; Picci P
Eur J Cancer; 2005 Dec; 41(18):2836-45. PubMed ID: 16298125
[TBL] [Abstract][Full Text] [Related]
27. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
28. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
29. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response.
Ng IO; Liu CL; Fan ST; Ng M
Am J Clin Pathol; 2000 Mar; 113(3):355-63. PubMed ID: 10705815
[TBL] [Abstract][Full Text] [Related]
30. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
31. [Expression of hypoxia-inducible factor 1α in osteosarcoma and its value in predicting chemosensitivity].
Chen Y; Wang CM; Shi YQ; Yang Y
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):899-904. PubMed ID: 23336375
[TBL] [Abstract][Full Text] [Related]
32. Osteosarcoma: the state of affairs dictates a change. What do we know?
Kleinerman ES; Mary V; John A
Adv Exp Med Biol; 2014; 804():vii-viii. PubMed ID: 25207354
[No Abstract] [Full Text] [Related]
33. Chemotherapy for Bone Sarcoma in Adults.
Wagner MJ; Livingston JA; Patel SR; Benjamin RS
J Oncol Pract; 2016 Mar; 12(3):208-16. PubMed ID: 26962160
[TBL] [Abstract][Full Text] [Related]
34. The role of pharmacogenetics in the treatment of osteosarcoma.
Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
[TBL] [Abstract][Full Text] [Related]
35. Factors that Influence Chemotherapy Treatment Rate in Patients With Upper Limb Osteosarcoma.
Restrepo DJ; Huayllani MT; Boczar D; Sisti A; Spaulding AC; Moran SL; Aung T; Bagaria S; Manrique OJ; Forte AJ
Anticancer Res; 2019 Oct; 39(10):5611-5615. PubMed ID: 31570457
[TBL] [Abstract][Full Text] [Related]
36. The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma.
Pawinski A; Crowther D; Keizer HJ; Voûte PA; Somers R; van Glabbeke M; Lentz MA; van Oosterom AT
Eur J Cancer; 1999 Jan; 35(1):163-4. PubMed ID: 10211107
[No Abstract] [Full Text] [Related]
37. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group.
Isakoff MS; Goldsby R; Villaluna D; Krailo MD; Gorlick R; Doski JJ; Womer RB; Janeway KA
Pediatr Blood Cancer; 2016 Feb; 63(2):370-1. PubMed ID: 26376351
[No Abstract] [Full Text] [Related]
38. Genomic and transcriptomic characterization of pre-operative chemotherapy response in patients with osteosarcoma.
Yang Y; Huang Z; Yuan M; Rui J; Chen R; Jin T; Sun Y; Deng Z; Shan H; Niu X; Liu W
Sci Rep; 2023 Nov; 13(1):20914. PubMed ID: 38017005
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.
Hattinger CM; Patrizio MP; Luppi S; Serra M
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629971
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.
Sorensen FB; Jensen K; Vaeth M; Hager H; Funder AM; Safwat A; Keller J; Christensen M
Sarcoma; 2008; 2008():874075. PubMed ID: 19266050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
